BPC-157 Peptide Therapy Online (2026)
BPC-157 is a synthetic peptide used in peptide therapy protocols for tissue support. It is available through select telehealth platforms with clinical oversight.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
A synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice.
Adults working on tissue recovery protocols under clinical guidance.
Most platforms offer 4-8 week protocols with clinician check-ins.
Verified Offers for bpc-157
What the Studies Actually Show
BPC-157 is not an FDA-approved drug. The published evidence is preclinical (rodent and in-vitro). We are publishing the evidence summary below so that readers can evaluate the regulatory and scientific status before deciding whether the protocol is appropriate for them.
| Endpoint | Finding |
|---|---|
| BPC-157 — evidence base1 | Pre-clinical (rodent and in-vitro) studies suggest accelerated tendon, ligament, and gastrointestinal mucosal healing. No published Phase 2 or Phase 3 human trials. Not FDA-approved for any indication BPC-157 was added to the FDA's Category 2 list in 2023, reflecting the agency's view that significant safety questions or insufficient evidence currently preclude routine compounding for human use. Some 503A pharmacies still dispense it; reputable providers disclose the regulatory status. |
| Sermorelin (GHRH analog) — efficacy2 | Modest, transient increases in IGF-1 and growth hormone pulse amplitude in adults with adult-onset growth-hormone deficiency. Body composition effects are smaller than supraphysiologic GH replacement |
| Sermorelin — safety2 | Generally well tolerated; injection-site reactions are the most common adverse event. Long-term cancer-risk data are limited |
| FDA regulatory status of compounded peptides3 | Most popular peptides (BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295) are not FDA-approved drugs. Compounded availability is governed by FDA Sections 503A/503B and the agency's Category 1/2 lists |
- Sikiric P et al. — BPC-157 review, Curr Pharm Des 2018 · Sikiric P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Curr Pharm Des 2018;24(18):1990–2004.
- Sermorelin / GHRH analogs — Endocrine 2019 · Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006;1(4):307–308.
- FDA — Bulks Used in Compounding (Category 1/2 listings) · U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Sections 503A and 503B. Includes BPC-157, TB-500 and other peptides on the Category 2 list.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.